'
• Report Guidance
• GlobalData Clinical Trials Report Coverage
• Clinical Trials by Region
o Table Figure 1: Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region (%), 2017*
o Table Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Region, 2017*
o Clinical Trials and Average Enrollment by Country
Table Figure 2: Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Table Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Table Figure 3: Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Table Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Table Figure 4: Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017*
Table Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017*
Top Five Countries Contributing to Clinical Trials in Europe
Table Figure 5: Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
Table Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
Top Countries Contributing to Clinical Trials in North America
Table Figure 6: Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
Table Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, North America, Top Countries, 2017*
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Table Figure 7: Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017*
Table Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017*
Top Five Countries Contributing to Clinical Trials in Central and South America
Table Figure 8: Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017*
Table Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017*
• Clinical Trials by G7 Countries: Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials
o Table Figure 9: Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2017*
o Table Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, G7 Countries (%), 2017*
• Clinical Trials by Phase in G7 Countries
o Table Figure 10: Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
o Table Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
• Clinical Trials in G7 Countries by Trial Status
o Table Figure 11: Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
o Table Chronic Lymphocytic Leukemia (CLL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
• Clinical Trials by E7 Countries: Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials
o Table Figure 12: Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2017*
o Table Proportion of Chronic Lymphocytic Leukemia (CLL) to Oncology Clinical Trials, E7 Countries (%), 2017*
• Clinical Trials by Phase in E7 Countries
o Table Figure 13: Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
o Table Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
• Clinical Trials in E7 Countries by Trial Status
o Table Figure 14: Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
o Table Chronic Lymphocytic Leukemia (CLL) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
• Clinical Trials by Phase
o Table Figure 15: Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase (%), 2017*
o Table Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Phase, 2017*
o In Progress Trials by Phase
Table Figure 16: Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
Table Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
• Clinical Trials by Trial Status
o Table Figure 17: Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2017*
o Table Chronic Lymphocytic Leukemia (CLL) Therapeutics, Global, Clinical Trials by Trial Status, 2017*
• Clinical Trials by End Point Status
o Table Figure 18: Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2017*
o Table Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, by End Point Status, 2017*
• Subjects Recruited Over a Period of Time
o Table Figure 19: Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
o Table Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
• Clinical Trials by Sponsor Type
o Table Figure 20: Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
o Table Chronic Lymphocytic Leukemia (CLL) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
• Prominent Sponsors
o Table Figure 21: Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
o Table Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
o Top Companies Participating in Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials
Table Figure 22: Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Table Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
• Prominent Drugs
o Table Figure 23: Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
o Table Chronic Lymphocytic Leukemia (CLL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
• Latest Clinical Trials News on Chronic Lymphocytic Leukemia (CLL)
o Jun 23, 2017: Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers
o Jun 16, 2017: BeiGene Presents Initial Phase 1 Data on BTK Inhibitor BGB-3111 Combined with Obinutuzumab at the 14th International Conference on Malignant Lymphoma and Announces Additional Planned Global Registrational Trials for BGB-3111
o Jun 16, 2017: TG Therapeutics Recaps Positive Data from the Phase 3 GENUINE Trial and Data from the Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 14th International Conference on Malignant Lymphoma
o Jun 14, 2017: BeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the 14th International Conference on Malignant Lymphoma
o Jun 13, 2017: TG Therapeutics Recaps Schedule of Clinical Data Presentations of TGR-1202 at the Upcoming 14th International Conference on Malignant Lymphoma & the 22nd European Hematology Association Annual Congress
o Jun 12, 2017: AbbVie Announces New Data Evaluating Venetoclax in a Variety of Hematologic Malignancies at the 22nd European Hematology Association Congress
o Jun 08, 2017: TG Therapeutics to Present Clinical Data of Ublituximab at the Upcoming 14th International Conference on Malignant Lymphoma
o Jun 07, 2017: Verastem to Present Long-Term Follow-Up Data from the DYNAMO Study at the 14th International Conference on Malignant Lymphoma
o Jun 07, 2017: BeiGene to Present Data on BGB-3111 at the 14th International Conference on Malignant Lymphoma and to Host Conference Call
o Jun 05, 2017: New Data Presented at ASCO 2017 Finds IMBRUVICA (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
o Jun 05, 2017: Long-Term IMBRUVICA (ibrutinib) Efficacy and Safety Data at ASCO 2017 Show Sustained Survival Rates in Up to Four Years in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients, Including Those with High-Risk Disease
o Jun 03, 2017: TG Therapeutics Announces Positive Data from Phase 3 GENUINE Trial of TG-1101 in Combination with Ibrutinib in Patients with High Risk Chronic Lymphocytic Leukemia at the 53rd Annual Meeting of the American Society of Clinical Oncology
o Jun 02, 2017: TG Therapeutics Recaps Schedule of Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology
o May 31, 2017: MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma
o May 31, 2017: Personalized cell therapy combination achieves complete remission in CLL patients
o May 30, 2017: Novartis next generation CAR-T cell therapy CTL119 combined with ibrutinib shows high rate of responses in CLL patients
o May 19, 2017: TG Therapeutics Announces Data on TG-1101 at the Upcoming 14th International Conference on Malignant Lymphoma
o May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association
o May 17, 2017: Janssen to Present Data on Ibrutinib at the American Society of Clinical Oncology
o May 17, 2017: TG Therapeutics Recaps Clinical Data Presentations at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology
o May 15, 2017: Preclinical data for reversible BTK inhibitor RXC005 presented at the 17th International Workshop of Chronic Lymphocytic Leukemia
o May 14, 2017: IMBRUVICA (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
o May 08, 2017: OHSU and Aptose Present CG'806 Preclinical Data Demonstrating Potent Activity Against Patient Samples at AACR Hematologic Malignancies Meeting
o Apr 20, 2017: TG Therapeutics Announces Clinical Data Presentations on TGR-1202 at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology
o Apr 20, 2017: TG Therapeutics Announces Clinical Data Presentations on TG-1101 at the Upcoming 53rd Annual Meeting of the American Society of Clinical Oncology
o Apr 11, 2017: ArQule Receives Clearance of Investigational New Drug Application from the FDA for Proprietary Reversible BTK Inhibitor, ARQ 531
o Apr 03, 2017: Sunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting
o Mar 30, 2017: After Much Anticipation, Cellectar Biosciences Initiates NCI-Supported Phase II Trial of CLR 131 in Multiple Myeloma and Other Blood Cancers
• Clinical Trial Profile Snapshots
• Appendix
o Abbreviations
o Definitions
o Research Methodology
Table Figure 24: GlobalData Methodology
o Secondary Research
o About GlobalData
o Contact Us
o Disclaimer
o Source
